The primary objective of the Biostatistics/Data Management Core is to facilitate and manage experimental design and statistical data analysis through consultation and collaboration at Johns Hopkins University, University of Alabama at Birmingham and University of Colorado at Boulder.
The specific aims of the Core include biostatistical consultation and support to all projects in the program, by assisting in the study design, data collection, quantitative modeling, publication, as well as interpretation, visualization and analysis of data arising in the course of program activities. The Core will also provide assistance with the identification and solution of complex database tasks arising in the course of project activities - this includes integration of clinical and basic research databases and interfaces for data entry, data retrieval, patient or sample tracking, and procedures to ensure data quality, integrity, and confidentiality at JHU and UAB. This database will provide a centralized means to produce interim reports of projected progress, patient accrual, processing of specimens, completeness of data gathering, and monitoring of patient drop out or loss to follow-up. The Core also provides the infrastructural support, programming, and computer maintenance necessary for the biostatistical and data management activities within the program. Finally, the Core continues to provide support for the SPORE website development and maintenance. The Biostatistics/Data Management Core is led by Dr. Mei-Cheng Wang, Ph.D. from Johns Hopkins University and Dr. Sreelatha Meleth, Ph.D. from University of Alabama at Birmingham. The Core is comprised of biostatisticians and supporting personnel from both JHU and UAB. All projects and other cores of the SPORE will be supported by the Biostatistics/Data Management Core.

Public Health Relevance

The Biostatistics/Data Management Core aims to facilitate and manage experimental design and statistical data analysis and data management for the clinical trials conducted within the Cervical Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098252-10
Application #
8537834
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$238,630
Indirect Cost
$62,783
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Yang, Andrew; Farmer, Emily; Lin, John et al. (2016) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res :
Yang, Andrew; Farmer, Emily; Wu, T C et al. (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 141:364-70
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. J Low Genit Tract Dis 20:119-25
Jiang, Rosie T; Schellenbacher, Christina; Chackerian, Bryce et al. (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines 15:853-62
Wang, Yi-Shu; Chen, Jianfeng; Cui, Fengmei et al. (2016) LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget :
Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Randles, Leah; Anchoori, Ravi K; Roden, Richard B S et al. (2016) The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem 291:8773-83
Yang, Andrew; Jeang, Jessica; Cheng, Kevin et al. (2016) Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 15:989-1007

Showing the most recent 10 out of 251 publications